Bausch Health names Seana Carson as General Counsel effective Bausch + Lomb IPO closing

Bausch Health Companies Inc.

Christina Ackermann will become General Counsel of Bausch + Lomb upon IPO closing.
Joseph Gordon transfers to Bausch + Lomb to lead global consumer, vision care, surgical and EMEA pharma.
Seana Carson appointed General Counsel of Bausch Health, effective IPO closing.
Seana Carson base salary CA$665,000; cash incentive 60% of base; US$250,000 RSU grant.
Changes part of previously announced separation of Bausch + Lomb via IPO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Seana Carson

General Counsel

BHC · Bausch Health Companies Inc.

Filed: September 30, 2021, 7:59 PM ET

In connection with Christina Ackermann’s Bausch + Lomb appointment, Seana Carson, Senior Vice President of Legal, will be appointed General Counsel of Bausch Health, effective as of the IPO Closing Date.

Departed

Joseph Gordon

Other Named Officer

BHC · Bausch Health Companies Inc.

Filed: September 30, 2021, 7:59 PM ET

Joseph Gordon will also transfer with Bausch + Lomb, effective as of the IPO Closing Date, where he will lead Bausch + Lomb’s global consumer, vision care and surgical businesses as well as the EMEA ophthalmology pharmaceutical business.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Seana Carson was appointed as General Counsel at Bausch Health Companies Inc..

Action: appointed
Role: General Counsel

Exact text from the filing

In connection with Christina Ackermann’s Bausch + Lomb appointment, Seana Carson, Senior Vice President of Legal, will be appointed General Counsel of Bausch Health, effective as of the IPO Closing Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Joseph Gordon departed as other_named_officer at Bausch Health Companies Inc..

Action: will transfer

Exact text from the filing

Joseph Gordon will also transfer with Bausch + Lomb, effective as of the IPO Closing Date, where he will lead Bausch + Lomb’s global consumer, vision care and surgical businesses as well as the EMEA ophthalmology pharmaceutical business.

View on SEC.gov

Bausch Health Companies Inc. filing history →

Source: SEC EDGAR

accession 0000885590-21-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.